## 1. Abstract (150 words)

Type 2 diabetes (T2D) and Alzheimer’s disease (AD) are epidemiologically and biologically linked, but shared brain molecular programs remain incompletely defined. We analyzed the human brain microarray dataset GSE5281 (161 samples; 87 AD, 74 controls; 21,655 genes) to test hypotheses spanning insulin/PI3K-AKT signaling failure, GSK3B-associated stress, mitochondrial oxidative phosphorylation (OXPHOS) suppression, and inflammatory extracellular-matrix (ECM) remodeling (including MMP9/IL-17–related biology). Available outputs indicate substantial transcriptomic structure (PCA: PC1 17.96%, PC2 13.89%, PC3 5.72%), large-scale differential expression (6,378 genes at FDR<0.05), and 17 enriched pathways with IFN-γ response as top signal (q=7.36×10^-6), consistent with immune activation. However, critical analyses failed in multiple runs (ImportError, failed pathway-enrichment/heatmap), and key gene-level evidence (e.g., MMP9 statistics, PI3K-AKT gene shifts, OXPHOS gene list) was not reported. Therefore, evidence supports a broad inflammatory AD signature but remains insufficient to conclusively establish specific AD–T2D shared causal drivers.

---

## 2. Introduction

T2D increases risk for cognitive decline and AD, motivating the concept of “type 3 diabetes,” in which impaired insulin signaling, mitochondrial dysfunction, and chronic inflammation converge in the brain. Mechanistically, reduced neuronal insulin receptor signaling can depress PI3K-AKT activity and disinhibit GSK3B, potentially accelerating tau pathology and synaptic dysfunction. In parallel, metabolic stress can trigger innate immune activation and ECM remodeling (e.g., MMP family), while mitochondrial OXPHOS failure and oxidative stress may reinforce neurodegeneration.

Despite strong conceptual links, robust transcriptomic evidence for shared AD–T2D programs in human brain tissue is often inconsistent across studies and pipelines. The present investigation used GSE5281 (AD vs aged controls) to test whether AD brain tissue carries a diabetes-like expression signature, with emphasis on:  
1) insulin/PI3K-AKT downregulation and GSK3B-associated programs,  
2) inflammatory/ECM modules centered on MMP9 and IL-17/leukocyte pathways, and  
3) mitochondrial OXPHOS suppression.

This question is clinically important because validated shared drivers could support repurposing of metabolic or anti-inflammatory interventions for neurodegeneration.

---

## 3. Methods

### Dataset
- **GSE5281**: postmortem human brain expression dataset.  
- **Samples**: 161 total (87 AD, 74 controls).  
- **Features**: 21,655 genes.

### Planned analytical framework
The investigation intended to perform:
1. **Quality structure analysis** (PCA).  
2. **Differential expression (DE)** between AD and controls with multiple-testing correction (FDR).  
3. **Pathway enrichment** for DE genes (immune, insulin/PI3K-AKT, OXPHOS, ECM/IL-17).  
4. **Module/network analyses** (including candidate-centric interpretation such as MMP9).  
5. **Hypothesis scoring/posteriors** from integrated evidence.

### Statistical outputs available
- PCA variance explained by leading components.  
- Number of DE genes at FDR threshold.  
- Number of enriched pathways and top hit with q-value.

### Critical execution issues
Multiple experiment logs reported failures:
- `ImportError: '__import__ not found'`
- failed `pathway_enrichment`
- failed heatmap/module outputs.

These failures materially limit interpretability, especially for gene-level effect sizes, pathway breadth, and causal-priority claims.

---

## 4. Results

### Global transcriptomic signal
- **PCA succeeded** and showed substantial structure/heterogeneity:
  - **PC1: 17.96%**
  - **PC2: 13.89%**
  - **PC3: 5.72%**
- Interpretation: AD/control differences likely coexist with strong biological/technical variability and potential outliers.

### Differential expression and enrichment (partial successful run)
From experiment `exp_d04ffeffd4`:
- **DE genes**: **6,378** at **FDR < 0.05**.
- **Enriched pathways**: **17** significant pathways.
- **Top pathway**: **IFN-γ response**, **q = 7.36e-06**.

This supports a strong immune/inflammatory signal in AD brain expression.

---

### Hypothesis-by-hypothesis outcomes

#### H1/H4/H7: Insulin-resistance-like signaling (PI3K-AKT down, GSK3B programs up; AD shows diabetes-like insulin resistance)
- **Posterior support (proposed):** 0.83, 0.79, 0.77 (from hypothesis layer).
- **Observed evidence in run outputs:** **insufficient**.
- No explicit reported DE statistics for core genes (e.g., **INSR, IRS1/2, PIK3CA/B, AKT1/2, GSK3B**), no pathway q-values for insulin signaling.
- **Conclusion:** biologically plausible but **not directly validated** by available outputs.

#### H2/H5: MMP9-centered neuroinflammatory ECM remodeling as shared AD–T2D driver
- **Posterior labels:** inconclusive 0.79 (H2), proposed 0.84 (H5).
- **Experiment `exp_0c647368fb` verdict:** inconclusive; key evidence missing.
- MMP9-specific DE not shown; IL-17/leukocyte/ECM enrichment outputs absent or failed.
- **Conclusion:** cannot confirm MMP9-centered mechanism from current computational evidence.

#### H3/H9: Mitochondrial energy failure/OXPHOS suppression as convergent AD–T2D signature
- **Posterior labels:** proposed 0.87 (H3), proposed 0.80 (H9).
- **Observed evidence:** no reported OXPHOS pathway statistics, no mitochondrial gene-level table.
- **Conclusion:** hypothesis remains **unresolved** in this run due to missing direct tests.

#### H6: Sleep/glymphatic-disruption inflammatory module overlap
- **Posterior:** inconclusive 0.62.
- **Experiment `exp_5bfcad62d1` verdict:** not testable due to import/enrichment/heatmap failures.
- **Conclusion:** no usable result.

#### H8: IL-17/leukocyte/monocyte-neutrophil bridge between AD and T2D immune dysfunction
- **Posterior:** inconclusive 0.69.
- **Experiment `exp_d04ffeffd4` strength:** 0.62 (partial support).
- Evidence supports broad inflammation (IFN-γ enrichment), but **specific IL-17/myeloid terms not explicitly reported**.
- **Conclusion:** partial directional support; not definitive.

---

## 5. Discussion

This investigation provides **credible but incomplete** evidence that AD brain tissue in GSE5281 is strongly immunologically perturbed, consistent with a potential overlap with T2D-related inflammatory biology. The scale of DE (6,378 genes, FDR<0.05) and significant enrichment of IFN-γ response (q=7.36×10^-6) align with established neuroimmune activation in AD.

However, the primary research question asked for **shared molecular mechanisms between T2D and AD**, including specific insulin-resistance and mitochondrial programs. Those claims require explicit pathway-level and gene-level statistics that were not successfully produced in the available run logs. Consequently, high-level posterior “proposed” labels should be interpreted as **model suggestions**, not confirmed findings.

### Major limitations
1. **Pipeline instability/failures** prevented key analyses.
2. **Missing effect-size reporting** (gene-wise log2FC/p-values for targets like MMP9, GSK3B, PI3K-AKT components).
3. **No formal cross-dataset integration with T2D brain data**, so “shared” is inferred rather than directly demonstrated.
4. Reported “extremely large” log2FC values (not shown in detail) raise potential normalization/scale concerns.
5. Potential confounding from brain-region heterogeneity, cell-type composition, and postmortem covariates.

### Recommended follow-up
- Re-run DE and enrichment with audited environment (e.g., limma + robust QC + covariate adjustment).
- Perform **cell-type deconvolution** and/or pseudobulk single-cell validation.
- Test predefined gene sets: insulin signaling, AKT/GSK3B targets, OXPHOS/ETC complexes, IL-17/myeloid, ECM remodeling.
- Quantify **MMP9** directly (DE, network centrality, module membership).
- Integrate external AD and T2D datasets (brain and peripheral) with meta-analysis and causal inference (e.g., Mendelian randomization where possible).

---

## 6. Conclusions

- The current analysis supports a **strong AD inflammatory transcriptomic phenotype** in GSE5281.
- Evidence is **insufficient** to conclusively establish the proposed AD–T2D shared mechanisms (insulin/PI3K-AKT impairment, GSK3B stress programs, MMP9-centered ECM remodeling, OXPHOS suppression) because key computational outputs were missing or failed.
- The work should be considered **hypothesis-generating**; definitive mechanistic conclusions require a reproducible re-analysis with full gene- and pathway-level reporting and direct cross-disease integration.

---

## 7. References

1. **Uncovering Spatiotemporal and Functional Dynamics of Long Non-coding RNAs During Alzheimer's Progression in the Human Brain at Single-Cell Resolution.** PMID: 42060014.  
2. **MMP9 as a shared immune-related gene in Alzheimer's and Huntington's diseases: a cross-tissue transcriptomic analysis.** PMID: 42030987.  
3. **Associations between sleep disturbance and cerebrospinal fluid Aβ, and shared proteomic signatures in Alzheimer's disease.** PMID: 41912985.  
4. **Transcranial direct current stimulation alters cerebrospinal fluid-interstitial fluid exchange in mouse brain.** bioRxiv: 10.1101/2023.12.30.573695.  
5. **KCNQ2/3 regulates efferent mediated slow excitation of vestibular afferents in mammals.** bioRxiv: 10.1101/2023.12.30.573731.